Tracon Pharmaceuticals, a public biopharmaceutical company in San Diego, announced Tuesday that Dr. Ronald Shazer has been appointed chief medical officer.

Shazer was most recently a senior director at Pfizer, where he led the clinical development of multiple immuno-oncology compounds. Prior to Pfizer, Shazer was director of clinical research oncology at Bristol-Myers Squibb from 2011 to 2013 and served as the lead on the registrational study for elotuzumab, which received FDA breakthrough therapy designation in 2014. Prior to Bristol-Myers Squibb, Shazer was head of clinical development at Arena Pharmaceuticals.

Shazer held academic positions in the Department of Medicine at the University of California, San Diego, University of California; Los Angeles School of Medicine; and Cedars-Sinai Medical Center.

Tracon (Nasdaq: TCON) develops targeted therapies for cancer, wet age-related macular degeneration, and fibrotic diseases. The company’s current pipeline includes two clinical stage product candidates: TRC105 and TRC102.